24242-97-5

Usage

Uses

Used in Fragrance and Flavor Industry:
1-(4-isobutoxyphenyl)ethanone is used as a key ingredient for creating various fragrances and flavors due to its appealing scent.
Used in Pharmaceutical Industry:
1-(4-isobutoxyphenyl)ethanone is utilized in the manufacturing of pharmaceuticals, contributing to the development of new medications.
Used in Organic Synthesis:
1-(4-isobutoxyphenyl)ethanone serves as a solvent in organic synthesis, facilitating chemical reactions in laboratory and industrial settings.
Used in Organic Electronics:
It has potential applications in the field of organic electronics, where its unique properties can be harnessed for innovative electronic devices and components.
Used as a Reagent in Chemical Reactions:
1-(4-isobutoxyphenyl)ethanone is employed as a reagent in various chemical reactions, aiding in the synthesis of different compounds.
It is important to handle 1-(4-isobutoxyphenyl)ethanone with care, as it may pose hazards if not used properly.

InChI:InChI=1/C12H16O2/c1-9(2)8-14-12-6-4-11(5-7-12)10(3)13/h4-7,9H,8H2,1-3H3

Upstream product

• 1126-75-6 (isobutyloxy)benzene 
• 108-24-7 acetic anhydride 
• 78-77-3 Isobutyl bromide 
• 99-93-4 4-Hydroxyacetophenone 

Downstream Products

• 63957-29-9 1-(4-isobutoxy-phenyl)-3-piperidino-propan-1-one; hydrochloride 
• 78382-11-3 C₁₃H₂₀N₄OS 
• 53704-76-0 α-bromo-4'-isobutoxyacetophenone 
• 308143-23-9 3-fluoro-2-[4-(2-methylpropyloxy)phenyl]-6-(ethyloxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one 
• 308143-22-8 2-fluoromethyl-1-[2-(4-isobutoxy-phenyl)-2-oxo-ethyl]-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester 
• 308143-24-0 3-fluoro-4-(2-fluorobenzyl)2-[4-(2-methylpropyloxy)phenyl]-6-(ethyloxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one 
• 1574394-72-1 ethyl 3-(4-isobutoxyphenyl)-3-oxopropanoate 

Relevant academic research and scientific papers

HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase

The identification of novel, non-purine based inhibitors of xanthine oxidase is described. After a high-throughput screening campaign, an NMR based counterscreen was used to distinguish actives, which interact with XO in a reversible manner, from assay artefacts. This approach identified pyrimidone 1 as a reversible and competitive inhibitor with good lead-like properties. A hit to lead campaign gave compound 41, a nanomolar inhibitor of hXO with efficacy in the hyperuricemic rat model after oral dosing.

Catalytic Friedel-Crafts acylation of alkoxybenzenes mediated by aluminum hydrogensulfate in solution and solvent-free conditions

Friedel-Crafts acylation of alkoxybenzenes was achieved efficiently by a reaction with aliphatic acid anhydrides in the presence of catalytic amounts of aluminum hydrogensulfate, Al(HSO4)3, in nitromethane and under solvent-free conditions. Alkylbenzenes and aryl halides, as well as aromatic anhydrides, remained intact under these conditions.

Catalytic Friedel-Crafts acylation of alkoxy benzenes by ferric hydrogensulfate

Friedel-Crafts acylation of alkoxy benzenes is achieved efficiently by reaction with aliphatic acid anhydrides in the presence of catalytic amounts of ferric hydrogensulfate, Fe(HSO4)3, in nitromethane. Alkyl benzenes and aryl halides, as well as aromatic anhydrides, remain intact under these conditions.

A novel synthesis of 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimid-4-ones as potent, stable GnRH receptor antagonists.

A new class of small molecule GnRH antagonists, the 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimid-4-ones, was designed and a novel synthesis for these compounds was developed. The synthesis utilizes a base-catalyzed intramolecular cyclization of fluoromethyl pyrimidone 5 to generate the bicyclic core. Amongst the compounds synthesized, we discovered some highly potent GnRH receptor antagonists (e.g., 12, K(i)=9 nM), which showed enhanced stability towards acidic physiological conditions compared to the des-fluoro analogues.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Ar, B, R1, R2, R3a, R3b, R4, R5, R6and m are as defined herein.